Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Nectin-4 ADC, Urothelial Cancer

Jonathan Rosenberg

MD

🏢Memorial Sloan Kettering Cancer Center🌐USA

Chief, Genitourinary Oncology Service

62
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Dr. Jonathan Rosenberg is a leading GU oncologist at MSK who has contributed to the development and evaluation of multiple ADCs in urothelial cancer. He has studied tisotumab vedotin as well as enfortumab vedotin and has investigated their mechanisms of action, toxicity profiles, and biomarkers of response. His laboratory research and clinical trial leadership have defined ADC therapy in bladder cancer.

Share:

🧪Research Fields 研究领域

tisotumab vedotin tissue factor ADC
enfortumab vedotin bladder
urothelial cancer biomarker
ADC toxicities management
muscle-invasive bladder cancer systemic therapy

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Jonathan Rosenberg 的研究动态

Follow Jonathan Rosenberg's research updates

留下邮箱,当我们发布与 Jonathan Rosenberg(Memorial Sloan Kettering Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment